Orthofix Medical Inc. OFIX
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
1.02
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $822.3M | -$92.2M | $566.0M | — | $450.0M |
| 2024 | $799.5M | -$126.0M | $545.9M | — | $503.1M |
| 2023 | $746.6M | -$151.4M | $486.3M | -$106.0M | $598.7M |
| 2022 | $460.7M | -$19.7M | $337.2M | -$32.9M | $336.9M |
| 2021 | $464.5M | -$38.4M | $349.6M | $690,000 | $336.9M |
| 2020 | $406.6M | $2.5M | $304.7M | $58.8M | $356.9M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.02 (distress)
- Working capital / assets 0.29
- Retained earnings / assets -0.433
- EBIT / assets -0.096
- Equity / liabilities 1.123
Source: SEC EDGAR filings · CIK 0000884624 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.